TY - JOUR
T1 - Shape analysis of subcortical structures in obsessive-compulsive disorder and the relationship with comorbid anxiety, depression, and medication use
T2 - A meta-analysis by the OCD Brain Imaging Consortium
AU - Fouche, Jean-Paul
AU - Groenewold, Nynke A.
AU - Sevenoaks, Tatum
AU - Heany, Sarah
AU - Lochner, Christine
AU - Alonso, Pino
AU - Batistuzzo, Marcelo C.
AU - Cardoner, Narcis
AU - Ching, Christopher R. K.
AU - de Wit, Stella J.
AU - Gutman, Boris
AU - Hoexter, Marcelo Q.
AU - Jahanshad, Neda
AU - Kim, Minah
AU - Kwon, Jun Soo
AU - Mataix-Cols, David
AU - Menchon, Jose M.
AU - Miguel, Euripedes C.
AU - Nakamae, Takashi
AU - Phillips, Mary L.
AU - Pujol, Jesus
AU - Sakai, Yuki
AU - Yun, Je-Yeon
AU - Soriano-Mas, Carles
AU - Thompson, Paul M.
AU - Yamada, Kei
AU - Veltman, Dick J.
AU - van den Heuvel, Odile A.
AU - Stein, Dan J.
N1 - Funding Information: FIS PI18/00856 grant, NIA T32AG058507, NIH grant U54 EB 020403, RO1MH117601, Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) (grant no. 2018R1A4A1025891), NIMH: P50MH106435, R37MH100041, R01MH115466, R01MH059929, R01MH060952 and the Pittsburgh Foundation, PI16/00889 and PI19/01171 grants from the Carlos III Heath Institute; PERIS SLT006/17/00249 grant from Generalitat de Catalunya, and NIH grant U54 EB 020403 Funding Information: The authors of this study were supported by FIS PI18/00856 grant, NIA T32AG058507, NIH grant U54 EB 020403, RO1MH117601, Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) (grant no. 2018R1A4A1025891), NIMH: P50MH106435, R37MH100041, R01MH115466, R01MH059929, R01MH060952 and the Pittsburgh Foundation, PI16/00889 and PI19/01171 grants from the Carlos III Heath Institute; PERIS SLT006/17/00249 grant from Generalitat de Catalunya, NIH grant U54 EB 020403 Funding Information: Christopher R. K. Ching received partial grant support from Biogen, Inc. (Boston, USA) for research unrelated to this manuscript. Boris Gutman receives financial support for consulting at Natera, Inc. (San Carlos, CA, USA) in research unrelated to the manuscript. Neda Jahanshad received partial grant support from Biogen, Inc. (Boston, USA) for research unrelated to this manuscript. Paul M. Thompson received partial grant support from Biogen, Inc. (Boston, USA) for research unrelated to this manuscript. Jose M. Menchon has received research funding, consultation or lecture fees from Janssen, AbBiotics, Exeltis, and Medtronic in the last 24 months unrelated to this manuscript. Funding Information: informationFIS PI18/00856 grant, NIA T32AG058507, NIH grant U54 EB 020403, RO1MH117601, Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) (grant no. 2018R1A4A1025891), NIMH: P50MH106435, R37MH100041, R01MH115466, R01MH059929, R01MH060952 and the Pittsburgh Foundation, PI16/00889 and PI19/01171 grants from the Carlos III Heath Institute; PERIS SLT006/17/00249 grant from Generalitat de Catalunya, and NIH grant U54 EB 020403The authors of this study were supported by FIS PI18/00856 grant, NIA T32AG058507, NIH grant U54 EB 020403, RO1MH117601, Basic Research Laboratory Program through the National Research Foundation of Korea (NRF) (grant no. 2018R1A4A1025891), NIMH: P50MH106435, R37MH100041, R01MH115466, R01MH059929, R01MH060952 and the Pittsburgh Foundation, PI16/00889 and PI19/01171 grants from the Carlos III Heath Institute; PERIS SLT006/17/00249 grant from Generalitat de Catalunya, NIH grant U54 EB 020403 Publisher Copyright: © 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
PY - 2022/10
Y1 - 2022/10
N2 - Objective: Neuroimaging studies of obsessive-compulsive disorder (OCD) patients have highlighted the important role of deep gray matter structures. Less work has however focused on subcortical shape in OCD patients. Methods: Here we pooled brain MRI scans from 412 OCD patients and 368 controls to perform a meta-analysis utilizing the ENIGMA-Shape protocol. In addition, we investigated modulating effects of medication status, comorbid anxiety or depression, and disease duration on subcortical shape. Results: There was no significant difference in shape thickness or surface area between OCD patients and healthy controls. For the subgroup analyses, OCD patients with comorbid depression or anxiety had lower thickness of the hippocampus and caudate nucleus and higher thickness of the putamen and pallidum compared to controls. OCD patients with comorbid depression had lower shape surface area in the thalamus, caudate nucleus, putamen, hippocampus, and nucleus accumbens and higher shape surface area in the pallidum. OCD patients with comorbid anxiety had lower shape surface area in the putamen and the left caudate nucleus and higher shape surface area in the pallidum and the right caudate nucleus. Further, OCD patients on medication had lower shape thickness of the putamen, thalamus, and hippocampus and higher thickness of the pallidum and caudate nucleus, as well as lower shape surface area in the hippocampus and amygdala and higher surface area in the putamen, pallidum, and caudate nucleus compared to controls. There were no significant differences between OCD patients without co-morbid anxiety and/or depression and healthy controls on shape measures. In addition, there were also no significant differences between OCD patients not using medication and healthy controls. Conclusions: The findings here are partly consistent with prior work on brain volumes in OCD, insofar as they emphasize that alterations in subcortical brain morphology are associated with comorbidity and medication status. Further work is needed to understand the biological processes contributing to subcortical shape.
AB - Objective: Neuroimaging studies of obsessive-compulsive disorder (OCD) patients have highlighted the important role of deep gray matter structures. Less work has however focused on subcortical shape in OCD patients. Methods: Here we pooled brain MRI scans from 412 OCD patients and 368 controls to perform a meta-analysis utilizing the ENIGMA-Shape protocol. In addition, we investigated modulating effects of medication status, comorbid anxiety or depression, and disease duration on subcortical shape. Results: There was no significant difference in shape thickness or surface area between OCD patients and healthy controls. For the subgroup analyses, OCD patients with comorbid depression or anxiety had lower thickness of the hippocampus and caudate nucleus and higher thickness of the putamen and pallidum compared to controls. OCD patients with comorbid depression had lower shape surface area in the thalamus, caudate nucleus, putamen, hippocampus, and nucleus accumbens and higher shape surface area in the pallidum. OCD patients with comorbid anxiety had lower shape surface area in the putamen and the left caudate nucleus and higher shape surface area in the pallidum and the right caudate nucleus. Further, OCD patients on medication had lower shape thickness of the putamen, thalamus, and hippocampus and higher thickness of the pallidum and caudate nucleus, as well as lower shape surface area in the hippocampus and amygdala and higher surface area in the putamen, pallidum, and caudate nucleus compared to controls. There were no significant differences between OCD patients without co-morbid anxiety and/or depression and healthy controls on shape measures. In addition, there were also no significant differences between OCD patients not using medication and healthy controls. Conclusions: The findings here are partly consistent with prior work on brain volumes in OCD, insofar as they emphasize that alterations in subcortical brain morphology are associated with comorbidity and medication status. Further work is needed to understand the biological processes contributing to subcortical shape.
KW - anxiety
KW - depression
KW - gray matter
KW - magnetic resonance imaging
KW - neuroimaging
KW - obsessive-compulsive disorder
KW - subcortical
UR - http://www.scopus.com/inward/record.url?scp=85137930937&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/brb3.2755
DO - https://doi.org/10.1002/brb3.2755
M3 - Article
C2 - 36106505
SN - 2162-3279
VL - 12
JO - Brain and Behavior
JF - Brain and Behavior
IS - 10
M1 - e2755
ER -